Insights and news
Stephenson Harwood advises Shield Therapeutics plc on exclusive Japan licence
Law firm Stephenson Harwood LLP has advised Shield Therapeutics plc on its exclusive licence agreement with VITAL-NET, Inc. for ACCRUFeR® in Japan.
Celebrating women in life sciences and healthcare: insights and challenges from Hannah Kuchler
Law firm Stephenson Harwood LLP recently held an event for women in life sciences and healthcare, to celebrate International Women's Day and the achievements of women working in the sector. The evening included a fireside chat with the Emmy-nominated, Loeb-winning Hannah Kuchler, Global Pharmaceutical Editor for the Financial Times, and Alexandra Pygall, head of life sciences and healthcare at Stephenson Harwood.
Stephenson Harwood advises Dr. Falk on acquisition of Kynos Therapeutics
Stephenson Harwood LLP has advised Dr. Falk Pharma GmbH ('Dr. Falk'), a German multi-national pharmaceutical company, on its successful acquisition of Kynos Therapeutics Ltd ('Kynos'), a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases.
Stephenson Harwood advises Hong Kong AI business on reverse merger and NASDAQ listing
Stephenson Harwood's Hong Kong corporate team has advised YOOV Group on its proposed reverse merger and listing on NASDAQ.
Stephenson Harwood advises on healthcare data acquisition
Stephenson Harwood LLP has acted for FPE Capital LLP on the acquisition by its portfolio company, Egress, of healthcare data migration specialist Stalis.
Stephenson Harwood advises Lansen Pharmaceutical on privatisation
Stephenson Harwood LLP acted as the Hong Kong legal adviser to Lansen Pharmaceutical Holdings Limited (Lansen Pharmaceutical) on its privatisation by Cathay International Pharma Manufacture And Distribution (China) Limited, involving a total consideration of approximately HK$240 million.
Stephenson Harwood advises on $25 million funding in ViaNautis Bio
Stephenson Harwood LLP has advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.
Stephenson Harwood advises BenevolentAI on strategic collaboration with Merck
Law firm Stephenson Harwood LLP has advised BenevolentAI on its recent strategic collaboration with Merck.
Stephenson Harwood advises Novacyt on Yourgene Health takeover
Law firm Stephenson Harwood LLP has advised long-standing diagnostics client Novacyt S.A. in relation to its recommended takeover of Yourgene Health plc, an international integrated technologies and services business which enables the delivery of genomic medicine.
Stephenson Harwood advises Flarin on fundraise
Law firm Stephenson Harwood LLP has advised Flarin, the joint pain relief brand, on its fundraise through existing investor IW Capital and through ITV's Media for Equity investment fund. ITV has agreed to invest up to £5 million of advertising inventory across its channels in return for a minority equity stake in Flarin. IW Capital has subscribed for new shares following previous equity investments in the Company. The Stephenson Harwood team was led by corporate partner Tom Page and included Naomi Leach, Tom O'Connor and Kate Ackland amongst others.
